ESR1 and breast carcinoma: HM3 and HM4, heparin mimetics initially developed to be safer and more selective anti-coagulants [73,74], were applied as concomitant treatments in a triple-negative MDA-MBA-231 and estrogen receptor-positive MCF-7 breast cancer cell models in our lab.